{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T02:17:09Z","timestamp":1793758629522,"version":"4.6.1"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca plc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009647","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009647","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.critrevonc.2026.105270","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T16:35:44Z","timestamp":1773419744000},"page":"105270","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Homologous recombination deficiency in Ovarian cancer: The game-changer for first-line maintenance therapy"],"prefix":"10.1016","volume":"222","author":[{"given":"Maria Chiara","family":"Cannizzaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Minucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Zormpas-Petridis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viola","family":"Ghizzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Fagotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenica","family":"Lorusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanda","family":"Salutari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Nero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105270_bib1","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-48667-6","article-title":"Histopathologic image\u2013based deep learning classifier for predicting platinum-based treatment responses in high-grade serous ovarian cancer","volume":"15","author":"Ahn","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105270_bib2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.6004\/jnccn.2021.0007","article-title":"Ovarian cancer, version 2.2020, NCCN clinical practice guidelines in oncology","volume":"19","author":"Armstrong","year":"2021","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.critrevonc.2026.105270_bib3","series-title":"StatPearls [Internet]","article-title":"Epithelial Ovarian Cancer. [accessed 3 March 2026]","author":"Arora","year":"2024"},{"key":"10.1016\/j.critrevonc.2026.105270_bib4","article-title":"Detection of homologous recombination deficiency (HRD) using a novel genomic and epigenomic liquid biopsy assay in patients with breast cancer","volume":"41","author":"Barbacioru","year":"2023"},{"key":"10.1016\/j.critrevonc.2026.105270_bib5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/path.4230","article-title":"Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling","volume":"231","author":"Bashashati","year":"2013","journal-title":"J. Pathol."},{"key":"10.1016\/j.critrevonc.2026.105270_bib6","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.1200\/JCO.23.02641","article-title":"Deep Learning Artificial Intelligence Predicts Homologous Recombination Deficiency and Platinum Response From Histologic Slides","volume":"42","author":"Bergstrom","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105270_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113978","article-title":"Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancer","volume":"202","author":"Boidot","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105270_bib8","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ygyno.2019.04.679","article-title":"Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data","volume":"154","author":"Cohen","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105270_bib9","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","article-title":"Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105270_bib10","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2026.105270_bib11","article-title":"Spatial and temporal intra-tumoral heterogeneity in advanced HGSOC: Implications for surgical and clinical outcomes","volume":"4","author":"Cunnea","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.critrevonc.2026.105270_bib12","article-title":"Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1\/GOG 3004 Trial","volume":"41","author":"DiSilvestro","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105270_bib13","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1158\/2159-8290.CD-17-0734","article-title":"Reversion Mutations with Clinical Use of PARP Inhibitors: Many Genes, Many Versions","volume":"7","author":"Domchek","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105270_bib14","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3390\/jmp4020012","article-title":"Analytical Validation and Clinical Utilization of the Oncomine Comprehensive Assay Plus Panel for Comprehensive Genomic Profiling in Solid Tumors","volume":"4","author":"Dumur","year":"2023","journal-title":"J. Mol. Pathol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105270_bib15","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1136\/jclinpath-2020-206762","article-title":"Establishment of a remote diagnostic histopathology service using whole slide imaging (digital pathology)","volume":"74","author":"Evans","year":"2021","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.critrevonc.2026.105270_bib16","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","article-title":"Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Gonz\u00e1lez-Mart\u00edn","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105270_bib17","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105270_bib18","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nature10762","article-title":"Clonal evolution in cancer","volume":"481","author":"Greaves","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105270_bib19","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.3390\/diagnostics13213293","article-title":"A Benchmark of In-House Homologous Recombination Repair Deficiency Testing Solutions for High-Grade Serous Ovarian Cancer Diagnosis","volume":"13","author":"Guarischi-Sousa","year":"2023","journal-title":"Diagnostics"},{"key":"10.1016\/j.critrevonc.2026.105270_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1405361","article-title":"Current HRD assays in ovarian cancer: differences, pitfalls, limitations, and novel approaches","volume":"14","author":"Guffanti","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105270_bib21","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2026.105270_bib22","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41379-021-00929-0","article-title":"Integrating digital pathology into clinical practice","volume":"35","author":"Hanna","year":"2022","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.critrevonc.2026.105270_bib23","doi-asserted-by":"crossref","first-page":"S584","DOI":"10.1016\/j.annonc.2024.08.837","article-title":"776P Liquid biopsy for the determination of homologous recombination deficiency in patients with high-grade serous ovarian cancer: Results of the BOVARY-pilot study","volume":"35","author":"Harl\u00e9","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105270_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00286","article-title":"Prevalence of homologous recombination\u2013related gene mutations across multiple cancer types","author":"Heeke","year":"2018","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105270_bib25","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/nrc2342","article-title":"DNA repair pathways as targets for cancer therapy","volume":"8","author":"Helleday","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105270_bib26","doi-asserted-by":"crossref","first-page":"17041","DOI":"10.1073\/pnas.1305170110","article-title":"Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance","volume":"110","author":"Johnson","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.critrevonc.2026.105270_bib27","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1158\/2159-8290.CD-17-0419","article-title":"Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma","volume":"7","author":"Kondrashova","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105270_bib28","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.annonc.2025.10.007","article-title":"Rucaparib maintenance for newly diagnosed advanced ovarian cancer: interim overall survival, progression-free survival, and safety at 5 years of follow-up from the phase III ATHENA-MONO\/GOG-3020\/ENGOT-ov45 study","volume":"37","author":"Kristeleit","year":"2026","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105270_bib29","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.annonc.2022.11.003","article-title":"Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1\/ENGOT-ov25 trial subgroup exploratory analysis","volume":"34","author":"Labidi-Galy","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105270_bib30","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.annonc.2023.11.015","article-title":"ESGO\u2013ESMO\u2013ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease","volume":"35","author":"Ledermann","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105270_bib31","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1158\/2159-8290.CD-18-0715","article-title":"BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma","volume":"9","author":"Lin","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105270_bib32","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s12915-024-02022-9","article-title":"Prediction of homologous recombination deficiency from routine histology with attention-based multiple instance learning in nine different tumor types","volume":"22","author":"Loeffler","year":"2024","journal-title":"BMC Biol."},{"key":"10.1016\/j.critrevonc.2026.105270_bib33","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1136\/ijgc-2023-004995","article-title":"Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1\/ENGOT-ov25 trial","volume":"34","author":"Lorusso","year":"2024","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105270_bib34","unstructured":"Lou, R.N., Jacobs, A., Wilder, A., Therkildsen, N.O., n.d. 1 A beginner\u2019s guide to low-coverage whole genome 2 sequencing for population genomics."},{"key":"10.1016\/j.critrevonc.2026.105270_bib35","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ejca.2023.04.020","article-title":"PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1\/ENGOT-ov25 trial","volume":"188","author":"Loverix","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105270_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115199","article-title":"Predicting benefit from PARP inhibitors using deep learning on H&E-stained ovarian cancer slides","volume":"216","author":"Marm\u00e9","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105270_bib37","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105270_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.08.2241","article-title":"Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial","author":"Monk","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105270_bib39","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1200\/JCO.22.01003","article-title":"A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA\u2013MONO\/GOG-3020\/ENGOT-ov45)","volume":"40","author":"Monk","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105270_bib40","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105270_bib41","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1200\/JCO.2010.34.2980","article-title":"Secondary Somatic Mutations Restoring BRCA1\/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas","volume":"29","author":"Norquist","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105270_bib42","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.molcel.2015.10.040","article-title":"Targeting the DNA Damage Response in Cancer","volume":"60","author":"O\u2019Connor","year":"2015","journal-title":"Mol. Cell"},{"key":"10.1016\/j.critrevonc.2026.105270_bib43","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.3390\/cancers15123095","article-title":"Prevalence of Homologous Recombination Deficiency in First-Line PARP Inhibitor Maintenance Clinical Trials and Further Implication of Personalized Treatment in Ovarian Cancer","volume":"15","author":"Paik","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105270_bib44","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nature14410","article-title":"Whole\u2013genome characterization of chemoresistant ovarian cancer","volume":"521","author":"Patch","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105270_bib45","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1136\/jcp-2023-208852","article-title":"In-house homologous recombination deficiency testing in ovarian cancer: a multi-institutional Italian pilot study","volume":"77","author":"Pepe","year":"2024","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.critrevonc.2026.105270_bib46","doi-asserted-by":"crossref","DOI":"10.1200\/PO.23.00348","article-title":"High Concordance of Different Assays in the Determination of Homologous Recombination Deficiency\u2013Associated Genomic Instability in Ovarian Cancer","author":"Pfarr","year":"2024","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105270_bib47","article-title":"GIInger predicts homologous recombination deficiency and patient response to PARPi treatment from shallow genomic profiles","volume":"4","author":"Pozzorini","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.critrevonc.2026.105270_bib48","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","article-title":"Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial","volume":"34","author":"Ray-Coquard","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105270_bib49","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105270_bib50","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s12325-024-02791-3","article-title":"Cost-Effectiveness Analysis of HRD Testing for Previously Treated Patients with Advanced Ovarian Cancer in Italy","volume":"41","author":"Rognoni","year":"2024","journal-title":"Adv. Ther."},{"key":"10.1016\/j.critrevonc.2026.105270_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114127","article-title":"Harmonization of homologous recombination deficiency testing in ovarian cancer: Results from the MITO16A\/MaNGO-OV2 trial","volume":"206","author":"Roma","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105270_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001789","article-title":"Spatial and Temporal Heterogeneity in High-Grade Serous Ovarian Cancer: A Phylogenetic Analysis","volume":"12","author":"Schwarz","year":"2015","journal-title":"PLOS Med"},{"key":"10.1016\/j.critrevonc.2026.105270_bib53","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105270_bib54","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1158\/0008-5472.CAN-08-0088","article-title":"Secondary BRCA1 mutations in BRCA1 -mutated ovarian carcinomas with platinum resistance","volume":"68","author":"Swisher","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2026.105270_bib55","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw148","article-title":"Mechanisms of therapy resistance in patient-derived xenograft models of BRCA1-deficient breast cancer","volume":"108","author":"Ter Brugge","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.critrevonc.2026.105270_bib56","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"The Cancer Genome Atlas Research Network","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105270_bib57","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ygyno.2024.01.016","article-title":"Concordance between an FDA-approved companion diagnostic and an alternative assay kit for assessing homologous recombination deficiency in ovarian cancer","volume":"184","author":"Wehn","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105270_bib58","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ygyno.2024.01.016","article-title":"Concordance between an FDA-approved companion diagnostic and an alternative assay kit for assessing homologous recombination deficiency in ovarian cancer","volume":"184","author":"Wehn","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105270_bib59","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3390\/ijms23010348","article-title":"Homologous Recombination Deficiencies and Hereditary Tumors","volume":"23","author":"Yamamoto","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105270_bib60","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1200\/JCO.22.01207","article-title":"Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study","volume":"40","author":"You","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105270_bib61","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/1471-0528.17324","article-title":"Genomic Scar Score: A robust model predicting homologous recombination deficiency based on genomic instability","volume":"129","author":"Yuan","year":"2022","journal-title":"BJOG Int. J. Obstet. Gynaecol."},{"key":"10.1016\/j.critrevonc.2026.105270_bib62","doi-asserted-by":"crossref","DOI":"10.21037\/gpm-23-19","article-title":"Homologous recombination deficiency score decreased after neoadjuvant chemotherapy in ovarian cancer patient: a case report","volume":"6","author":"Zhang","year":"2023","journal-title":"Gynecol. Pelvic Med."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001575?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001575?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T06:35:49Z","timestamp":1778481349000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826001575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":62,"alternative-id":["S1040842826001575"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105270","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Homologous recombination deficiency in Ovarian cancer: The game-changer for first-line maintenance therapy","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105270","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105270"}}